ArticleFrontiers in immunology2016
Postbiotic Modulation of Retinoic Acid Imprinted Mucosal-like Dendritic Cells by Probiotic Lactobacillus reuteri 17938 In Vitro.
Article in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 67 citations in OpenAlex.
- Extremely Preterm Infants Have Significant Alterations in Their Conventional T Cell Compartment during the First Weeks of Life.Journal of immunology (Baltimore, Md. : 1950) · 2020Trial
- The potency of native postbiotics and paraprobiotics in modulating inflammation by affecting the gut-kidney axis.Animal models and experimental medicine · 2026Article
- Postbiotics: a promising tool in personalized medicine approach for the inflammatory disorders.Molecular and cellular biochemistry · 2026Review
- Social and neuroendocrine phenotypes reprogrammed by endocrine-disrupting chemicals can be mitigated bybioRxiv : the preprint server for biology · 2026Article
- Demystifying the role of postbiotics in inflammation mediated metabolic disorders: an updated review.Food science and biotechnology · 2026Review
- Shifting from pro-inflammatory to regulatory: L. reuteri postbiotics modulate IL-17/IL-10 axis in LPS-induced HT-29 IBD model.Archives of microbiology · 2025Article
- Review
- Dysregulated Intestinal Host-Microbe Interactions in Systemic Lupus Erythematosus: Insights from Patients and Mouse Models.Microorganisms · 2025Review
- Postbiotic Metabolite Derived fromAntibiotics (Basel, Switzerland) · 2024Article
- The Impact of Bioactive Molecules from Probiotics on Child Health: A Comprehensive Review.Nutrients · 2024Review
- Acute Infectious Diarrhea.Advances in experimental medicine and biology · 2024Review
- Can Postbiotics Represent a New Strategy for NEC?Advances in experimental medicine and biology · 2024Review
- Use of Postbiotic as Growth Promoter in Poultry Industry: A Review of Current Knowledge and Future Prospects.Food science of animal resources · 2023Review
- Probiotics and Postbiotics as the Functional Food Components Affecting the Immune Response.Microorganisms · 2022Review
- Mineral-Enriched Postbiotics: A New Perspective for Microbial Therapy to Prevent and Treat Gut Dysbiosis.Biomedicines · 2022Review
- Human Gut Microbiome and Liver Diseases: From Correlation to Causation.Microorganisms · 2021Review
- Probiotics, Photobiomodulation, and Disease Management: Controversies and Challenges.International journal of molecular sciences · 2021Review
- Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body.Frontiers in immunology · 2021Review
- Immunomodulation of dendritic cells by Lactobacillus reuteri surface components and metabolites.Physiological reports · 2021Article
- The potential therapeutic role ofAmerican journal of translational research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactobacilli are widely used as probiotics with beneficial effects on infection-associated diarrhea, but also used in clinical trials of e.g., necrotizing enterocolitis and inflammatory bowel diseases. The possibility of using probiotic metabolic products, so-called postbiotics, is desirable as it could prevent possible side effects of live bacteria in individuals with a disturbed gut epithelial barrier. Here, we studied how Lactobacillus reuteri DSM 17938 cell-free supernatant (L. reuteri-CFS) influenced retinoic acid (RA)-driven mucosal-like dendritic cells (DC) and their subsequent effect on T regulatory cells (Treg) in vitro. RA clearly imprinted a mucosal-like DC phenotype with higher IL10 production, increased CD103 and CD1d expression, and a downregulated mRNA expression of several inflammatory-associated genes (NFκB1, RELB, and TNF). Treatment with L. reuteri-CFS further influenced the tolerogenic phenotype of RA-DC by downregulating most genes involved in antigen uptake, antigen presentation, and signal transduction as well as several chemokine receptors, while upregulating IL10 production. L. reuteri-CFS also augmented CCR7 expression on RA-DC. In cocultures, RA-DC increased IL10 and FOXP3 expression in Treg, but pre-treatment with L. reuteri-CFS did not further influence the Treg phenotype. In conclusion, L. reuteri-CFS modulates the phenotype and function of mucosal-like DC, implicating its potential application as postbiotic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.